E-ISSN: 1307-394X
Apremilast Treatment in Dermatology
PDF
Cite
Share
Request
Review
VOLUME: 10 ISSUE: 3
P: 0-0
September 2016

Apremilast Treatment in Dermatology

J Turk Acad Dermatol 2016;10(3):0-0
DOI: 10.6003/jtad.16103r1
Belma Türsen 1
Ulaş Güvenç 2
Ümit Türsen 3
1. Mersin State Hospital
2. Mersin Yenişehir Hospital
3. Mersin University, School of Medicine, Department of Dermatology, Mersin, Turkey
No information available.
No information available
PDF
Cite
Share
Request

ABSTRACT

Background:

Apremilast (Otezla®), an oral small molecule inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4), is under development with Celgene Corporation for the treatment of psoriatic arthritis, psoriasis, sarcoidosis, Behçet's syndrome, atopic dermatitis, and rheumatoid arthritis. Apremilast is indicated for the treatment of active psoriatic arthritis in adults. Apremilast has received its first global approval for this indication in the USA. Regulatory submissions for approval in this indication are under review in Canada and Europe. Regulatory filings have also been submitted for apremilast in the treatment of plaque psoriasis in the USA and Europe. Apremilast treatment have been reported in the following dermatologic diseases: psoriasis, rosacea, atopic dermatitis, contact dermatitis, sarcoidosis, lupus erythematosus, lichen planus and alopecia areata. The following article provides a summary of the salient points in relation to the clinical use of apremilast treatment in dermatology.